# AusperBio

> Clinical-stage oligonucleotide company developing ASO and targeted-siRNA candidates aimed at a functional cure for chronic hepatitis B.

## Why it is interesting

August 27, 2026: $120M Series C announced, bringing company-disclosed capital since 2024 to $360M. The lead is an unnamed strategic investor. RA Capital joined. Valuation was not disclosed. AHB-137 is in a Phase 3 trial in China and remains investigational.

## Profile

- **Latest funding:** Series C — $120M (August 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $120M
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-08-30
- **Latest funding investors:** Unnamed strategic investor, RA Capital Management, HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, CDH Investments

## Key facts

- Aug 27, 2026: $120M Series C; unnamed strategic lead; RA Capital new (PR Newswire)
- Company: $360M raised since 2024 — cumulative, not this round alone
- AHB-137 in Phase 3 in China; investigational, not approved
- AHB-171 is the first clinical Au-HALO siRNA candidate (company)
- No valuation. No /fund/ pages for RA Capital, Qiming, Sherpa, CDH

## Funding history

- Series C · $120M · August 2026
  Source: https://www.prnewswire.com/news-releases/ausperbio-completes-120-million-series-c-financing-to-advance-ahb-137-toward-potential-commercialization-and-expand-next-generation-hbv-therapies-302862321.html

## Related articles

- https://venturecapitaltracker.com/2026-ausperbio-120m-series-c-hbv
- https://venturecapitaltracker.com/2026-august-29-30-investment-news-biotech-robotics-docs
- https://venturecapitaltracker.com/2026-august-vc-news

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** August 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/ausperbio